author-photo

Jim Wang

Novartis

15

Papers

121

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

MP73-12 UNSUSPECTED METASTASES FOUND DURING SCREENING FOR A TRIAL OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

2015 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (6)
MP87-19 EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE RESULTS FROM IMPACT OF ABIRATERONE ACETATE IN PROSTATE-SPECIFIC ANTIGEN CORE STUDY

2015 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (15)
A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (48)
Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (16)
Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).

2007 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (9)